Titan Pharmaceuticals Inc
NASDAQ:TTNP

Watchlist Manager
Titan Pharmaceuticals Inc Logo
Titan Pharmaceuticals Inc
NASDAQ:TTNP
Watchlist
Price: 4.61 USD Market Closed
Market Cap: 6.1m USD

Titan Pharmaceuticals Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Titan Pharmaceuticals Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Titan Pharmaceuticals Inc
NASDAQ:TTNP
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Stock-Based Compensation
$1.3B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Stock-Based Compensation
$540m
CAGR 3-Years
5%
CAGR 5-Years
-10%
CAGR 10-Years
8%
Pfizer Inc
NYSE:PFE
Stock-Based Compensation
$751m
CAGR 3-Years
-9%
CAGR 5-Years
1%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Stock-Based Compensation
$802m
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Stock-Based Compensation
$631.8m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
12%
No Stocks Found

Titan Pharmaceuticals Inc
Glance View

Market Cap
6.1m USD
Industry
Pharmaceuticals

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. The company is headquartered in South San Francisco, California and currently employs 11 full-time employees. The firm is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.

TTNP Intrinsic Value
Not Available

See Also

Back to Top